2023 Annual Meeting | C46 - Cognitive, Behavioral, and Disease-modifying Therapeutics in Dementia

Date Sunday 04/23/23

Time 01:00 PM - 03:00 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Meredith Wicklund, MD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants should become familiar with the indication for and clinical utility of pharmacological and non-pharmacological therapeutics for dementia related cognitive and behavioral symptoms, and become familiar with the first ever disease modifying treatments for dementia and their role in clinical practice.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Systems-based Practice

Program Level Introductory

Program Tracks Advanced Practice Provider

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Event Timeline
01:00 PM - 01:35 PM EST	Speaker	Nonpharmacological Treatment of Behavioral Symptoms in Dementia Julio C. Rojas-Martinez, MD, PhD
01:35 PM - 02:10 PM EST	Speaker	Pharmacological Treatment of Cognitive and Behavioral Symptoms in Dementia Lealani M. Acosta, MD, MPH, FAAN
02:10 PM - 02:45 PM EST	Speaker	Disease Modifying Therapeutics in Dementia Meredith Wicklund, MD, FAAN
02:45 PM - 03:00 PM EST	Discussion	Questions and Answers Meredith Wicklund, MD, FAAN, Julio C. Rojas-Martinez, MD, PhD, Lealani M. Acosta, MD, MPH, FAAN

Faculty Disclosures
Meredith Wicklund, MD, FAAN	The institution of Dr. Wicklund has received research support from Arizona Alzheimer's Consortium. The institution of Dr. Wicklund has received research support from NIH.
Julio C. Rojas-Martinez, MD, PhD	The institution of Dr. Rojas-Martinez has received research support from NIH/NIA. The institution of Dr. Rojas-Martinez has received research support from Eli Lilly. The institution of Dr. Rojas-Martinez has received research support from Eisai. Dr. Rojas-Martinez has received research support from Roon, Healthcare. The institution of Dr. Rojas-Martinez has received research support from Amylyx.
Lealani M. Acosta, MD, MPH, FAAN	Dr. Acosta has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. The institution of Dr. Acosta has received research support from AbbVie, Biohaven, Roche, NIH.